Interesting variations on how a disease is defined: Comparisons of von Willebrand disease and Glanzmann thrombasthenia [17]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 3, 2007, Pages 647-649

  Nurden, Alan T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; GENE PRODUCT; PROTEIN ITGA2; PROTEIN ITGA2B; PROTEIN ITGB3; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ALPHA2 INTEGRIN; BETA3 INTEGRIN; ITGA2B PROTEIN, HUMAN; ITGB3 PROTEIN, HUMAN;

BLEEDING; DISEASE CLASSIFICATION; GENE MUTATION; GENE NUMBER; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; GENOTYPE; GLANZMANN DISEASE; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN VARIANT; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; GENETICS; METABOLISM; NOTE; PHENOTYPE;

GENOTYPE; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; PHENOTYPE; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBASTHENIA; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 34247385298     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02368.x     Document Type: Letter

References (16)

1. Sadler JE, Budde U, Eikenboom CJ, Favaloro EJ, Hill FGH, Holmberg L, Ingersley J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB. and the Working Party on Von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: A report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
2. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-95.
3. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1: 10-8.
4. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005; 3: 1773-82.
5. Ruiz C, Liu C-Y, Sun Q-H, Sigaud-Fiks M, Fressinaud E, Muller JY, Nurden P, Nurden AT, Newman P, Valentin N. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (αIIbβ3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001; 98: 2432-41.
6. Hardisty R, Pidard D, Cox A, Nokes T, Legrand C, Bouillot C, Pannocchia A, Heilmann E, HourdilléP, Bellucci S, Nurden A. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: The cause of a lifelong bleeding disorder. Blood 1992; 80: 696-708.
7. 995 to Gln (Q) aminoacid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin α IIb subunit in a patient with an unusual variant form of Glanzmann's thrombasthenia. Blood 1998; 92: 4178-87.
8. Nurden AT, Breillat C, Jacquelin B, Combrie R, Freedman JJ, Blanchette VS, Schmugge M, Rand ML. Triple Heterozygosity in the Integrin αIIb Subunit in a Patient with Glanzmann Thrombasthenia. J Thromb Haemost 2004; 2: 813-9.
9. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92: 2382-8.
10. Jacquelin B, Rozenshteyn D, Kanaji S, Koziol JA, Nurden AT, Kunicki TJ. Characterization of inherited differences in transcription of the human integrin alpha 2 gene. J Biol Chem 2001; 276: 231518-24.
11. Cheli Y, Kunicki TJ. hnRNP L regulates differences in expression of mouse integrin α2β1. Blood 2006; 107: 4391-8.
12. Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type I phenotypes. Blood 2004; 104: 2359-67.
13. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Soteh MH, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I. Phenotype and genotype of a cohort of families historically diagnosed with type I von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type I von Willebrand disease (MCMDM-1VWD). Blood 2007; 109: 112-21.
14. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PHB, Hay C, Collins P. on behalf of the UK Haemophilia Centre Doctors Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type I von Willebrand disease. Thromb Haemost 2006; 96: 630-41.
15. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-64.
16. Lemmerhirt HL, Shavit JA, Levy GG, Cole SM, Long JC, Ginsberg D. Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene. Blood 2006; 108: 3061-7.